PDCD1 and neoplasm: This study characterized the physiochemical and biological properties of JS207 and evaluated the therapeutic potential of this novel anti-PD-1/anti-VEGF BsAb through assessing antigen binding affinity, T cell activation, HUVEC proliferation inhibition, and in vivo anti-tumor efficacy.